A process for obtaining HMG-UP (human menopausal gonadotropin with ultra-purity grade) composition by removal of non gonadotropin contaminants as plasma serine protease inhibitor, afamin, insulin-like growth factor binding protein 7, zinc alpha-2-glycoprotein and albumin characterized by comprising the steps of: i) performing a treatment of an acidified human menopausal/postmenopausal urine with kaolin wherein gonadotropins and non-gonadotropin proteins present in urine are adsorbed in kaolin; ii) eluting the gonadotropins adsorbed in kaolin by alkaline elution which are separate in a fraction; iii) precipitating the fraction by with acetone for obtaining the Fraction A; iv) a bioactive fraction is extracted from this precipitate Fraction A with 10% w/v solution of ammonium acetate in ethanol (70 %) and precipitated with 10 % ammonium acetate in ethanol (90 %) to obtain Fraction B; v) performing a purification of the Fraction B by ion-exchange chromatography for obtaining a fraction C (HMG Source Material or equivalent)); vi) performing a purification of the Fraction C by cation exchange chromatography using a strong cationic resin, eluting with ammonium acetate; vii) precipitating in acid medium obtaining a Fraction F from the eluted obtained above; viii) purification of the Fraction F by anion exchange chromatography using a strong anionic resin, eluting with ammonium acetate for obtaining of a Fraction G; ix) purification of the gonadotropins obtained in Fraction G using hydrophobic interaction chromatography by sequential addition of buffers which contains decreasing concentration of ammonium sulfate, Fractions J2 and J3, wherein Fraction J2 has mostly FSH bioactivity and Fraction J3 has LH bioactivity; x) purification of the gonadotropin of Fraction J3 using a strong anion exchanger with multimodal functionality, eluting with a buffer at a constant pH but modifying the conductivity obtaining a Fraction J3-UP which only has LH activity; xi) obtaining of a Fraction HMG-UP in a balancing step by mixing of equivalent bioactivities of FSH in Fraction J2 and LH in Fraction J3-UP; xii) subjecting said fraction HMG-UP solution to the steps of: 1) sterile filtration, 2) nanofiltration, and 3) precipitation; in order to obtain a HMG-UP (human menopausal gonadotropin with ultra-purity grade) composition free of non-gonadotropincontaminants protease inhibitor, afamin, insulin-like growth factor binding protein 7, zinc alpha-2-glycoprotein and albumin. i) performing a treatment of an acidified human menopausal/postmenopausal urine with kaolin wherein gonadotropins and non-gonadotropin proteins present in urine are adsorbed in kaolin; ii) eluting the gonadotropins adsorbed in kaolin by alkaline elution which are separate in a fraction; iii) precipitating the fraction by with acetone for obtaining the Fraction A; iv) a bioactive fraction is extracted from this precipitate Fraction A with 10% w/v solution of ammonium acetate in ethanol (70 %) and precipitated with 10 % ammonium acetate in ethanol (90 %) to obtain Fraction B; v) performing a purification of the Fraction B by ion-exchange chromatography for obtaining a fraction C (HMG Source Material or equivalent)); vi) performing a purification of the Fraction C by cation exchange chromatography using a strong cationic resin, eluting with ammonium acetate; vii) precipitating in acid medium obtaining a Fraction F from the eluted obtained above; viii) purification of the Fraction F by anion exchange chromatography using a strong anionic resin, eluting with ammonium acetate for obtaining of a Fraction G; ix) purification of the gonadotropins obtained in Fraction G using hydrophobic interaction chromatography by sequential addition of buffers which contains decreasing concentration of ammonium sulfate, Fractions J2 and J3, wherein Fraction J2 has mostly FSH bioactivity and Fraction J3 has LH bioactivity; x) purification of the gonadotropin of Fraction J3 using a strong anion exchanger with multimodal functionality, eluting with a buffer at a constant pH but modifying the conductivity obtaining a Fraction J3-UP which only has LH activity; xi) obtaining of a Fraction HMG-UP in a balancing step by mixing of equivalent bioactivities of FSH in Fraction J2 and LH in Fraction J3-UP; xii) subjecting said fraction HMG-UP solution to the steps of: 1) sterile filtration, 2) nanofiltration, and 3) precipitation; 1) sterile filtration, 2) nanofiltration, and 3) precipitation;